Is Taxane-Cisplatin-Fluorouracil Superior to Cisplatin-Fluorouracil As Induction Chemotherapy in Outcome in Locally Advanced Head and Neck Cancers?

Tural, Deniz; Kilickap, Saadetin

doi:10.1200/jco.2013.52.5592

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among agents introduced in the 1990s, taxanes have shown great promise for the treatment of head and neck squamous cell carcinoma (HNSCC) (Schrijvers and Vermorken 2000 ). The clinical efficacy of induction chemotherapy using a PF regimen doubled while a three-drug combination of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) is still undergoing evaluation in several randomized controlled trials (RCTs) with varying results (Blanchard et al 2013 ; Forastiere et al 2013 ; Tural and Kilickap 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety

Qian

Hoffmann

et al. 2015

SpringerPlus

View full text Add to dashboard Cite

BackgroundThe objective of this study was to compare the efficacy and safety of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil (PF) regimen by a meta-analysis of data retrieved from the literature.MethodsSeven randomized clinical trials were identified, which included patients with advanced head and neck cancer who underwent induction chemotherapy with either a Tax-PF or PF protocol. The outcomes included the 3-year and 5-year overall survival (OS) and progression-free survival (PFS), overall response rate (ORR) and different types of adverse events.ResultsThe 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P = 0.008), 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43; P = 0.002), 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P = 0.003), 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70; P = 0.001) and ORR to chemotherapy (OR 1.66; 95% CI, 1.35 to 2.05; P < 0.001) of the patients in the Tax-PF group were statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P < 0.001), alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P < 0.001), diarrhea (OR 1.57; 95% CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P < 0.001) was higher in the Tax-PF group.ConclusionThe Tax-PF induction chemotherapy improved PFS and OS, and the ORR was better as compared to PF-based therapy regimens at the cost of a higher incidence of adverse events.Electronic supplementary materialThe online version of this article (doi:10.1186/s40064-015-0988-5) contains supplementary material, which is available to authorized users.

show abstract